Rhythm is developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
Developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
Learn More >
Our lead peptide product candidate, setmelanotide, is a potent, first-in-class MC4R agonist for the treatment of rare genetic disorders of obesity.
LEARN ABOUT OUR PRODUCT PIPELINE >
The Genetic Obesity Project website sponsored by Rhythm is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects.
VISIT WEBSITE >
January 4, 2018
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
November 11, 2017
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
VIEW ALL NEWS >